Skip to main content
. 2021 Jan 21;162(4):bqab013. doi: 10.1210/endocr/bqab013

Figure 1.

Figure 1.

Growth curves of MNU-induced mammary tumors in SDRs treated with supplemental GH from first appearance of tumor up to doxorubicin treatment start. When GH was halted, (indicated by the dashed line), some tumors continued to grow or resumed growth after an initial regression [SDRs #1, 2, 3, 4 (L5), 5 (L2), 9, 10, and 11 (L2)], new tumors emerged [SDRs #5 (R2, M5), 7 (R2, M5), and 8 (R2)], and some tumors regressed [SDRs #4 (R5), 6, 7(L3), 8 (L5), 9 (R2-1), and 11 (R2)].